See more : PT Kalbe Farma Tbk. (PTKFY) Income Statement Analysis – Financial Results
Complete financial analysis of Apollo Endosurgery, Inc. (APEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apollo Endosurgery, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Private Equity Holding AG (PEHN.SW) Income Statement Analysis – Financial Results
- Prime Mining Corp. (PRYM.TO) Income Statement Analysis – Financial Results
- Korea Circuit Co., Ltd. (007815.KS) Income Statement Analysis – Financial Results
- Greentech Technology International Limited (0195.HK) Income Statement Analysis – Financial Results
- Under Armour, Inc. (0R2I.L) Income Statement Analysis – Financial Results
Apollo Endosurgery, Inc. (APEN)
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.86M | 62.99M | 42.05M | 50.71M | 60.85M | 64.31M | 64.87M | 1.60M | 5.08M | 7.99M | 6.69M | 9.39M | 7.84M | 11.91M | 2.86M | 372.35K | 511.86K | 743.27K |
| Cost of Revenue | 34.43M | 28.03M | 19.81M | 25.04M | 27.66M | 24.58M | 25.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 42.43M | 34.96M | 22.24M | 25.68M | 33.19M | 39.73M | 39.61M | 1.60M | 5.08M | 7.99M | 6.69M | 9.39M | 7.84M | 11.91M | 2.86M | 372.35K | 511.86K | 743.27K |
| Gross Profit Ratio | 55.20% | 55.50% | 52.90% | 50.63% | 54.55% | 61.78% | 61.07% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 11.91M | 9.52M | 7.67M | 10.38M | 12.18M | 8.30M | 7.81M | 8.51M | 18.13M | 11.34M | 8.16M | 9.73M | 7.82M | 6.63M | 10.12M | 12.42M | 4.04M | 1.48M |
| General & Administrative | 20.58M | 18.45M | 11.06M | 13.59M | 13.44M | 13.72M | 13.63M | 3.95M | 4.76M | 4.23M | 4.09M | 0.00 | 4.50M | 3.48M | 4.48M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 36.01M | 24.31M | 17.36M | 28.73M | 32.83M | 32.91M | 31.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 56.59M | 42.76M | 28.42M | 42.32M | 46.27M | 46.63M | 45.38M | 3.95M | 4.76M | 4.23M | 4.09M | 3.37M | 4.50M | 3.48M | 4.48M | 3.43M | 2.23M | 1.66M |
| Other Expenses | 1.75M | 1.88M | 1.95M | 2.10M | 7.07M | 7.24M | 7.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 70.25M | 54.16M | 38.04M | 54.80M | 65.52M | 62.17M | 60.37M | 12.46M | 22.89M | 15.58M | 12.25M | 13.10M | 12.32M | 10.11M | 14.60M | 15.85M | 6.28M | 3.15M |
| Cost & Expenses | 104.68M | 82.19M | 57.84M | 79.84M | 93.18M | 86.75M | 85.63M | 12.46M | 22.89M | 15.58M | 12.25M | 13.10M | 12.32M | 10.11M | 14.60M | 15.85M | 6.28M | 3.15M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 124.04K | 398.02K | 161.24K | 7.95K |
| Interest Expense | 4.67M | 8.32M | 5.25M | 4.05M | 4.06M | 4.51M | 18.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.12K | 27.95K | 0.00 | 157.13K |
| Depreciation & Amortization | -196.00K | 2.01M | 2.31M | 2.50M | 9.29M | 9.72M | 9.09M | 466.99K | 216.09K | 196.22K | 187.50K | 141.99K | 165.30K | 176.69K | 215.02K | 156.44K | 49.57K | 81.18K |
| EBITDA | -31.42M | -17.19M | -13.49M | -26.62M | -40.09M | -12.76M | -20.76M | -9.54M | -17.81M | -7.59M | -5.56M | -2.97M | 0.00 | 0.00 | -11.23M | -15.48M | -5.56M | -2.40M |
| EBITDA Ratio | -36.46% | -27.28% | -32.08% | -52.49% | -52.98% | -19.85% | -20.84% | -596.55% | -321.60% | -79.74% | -38.35% | -31.66% | -56.62% | 34.93% | -392.60% | -4,003.61% | -1,085.29% | -344.22% |
| Operating Income | -27.82M | -19.20M | -15.79M | -29.12M | -40.09M | -22.44M | -20.76M | -10.86M | -17.81M | -7.59M | -5.56M | -3.71M | -4.49M | 1.80M | -11.74M | -15.48M | -5.77M | -2.40M |
| Operating Income Ratio | -36.20% | -30.48% | -37.56% | -57.43% | -65.88% | -34.89% | -32.00% | -678.87% | -350.46% | -95.05% | -83.16% | -39.52% | -57.29% | 15.13% | -410.16% | -4,156.30% | -1,126.47% | -323.39% |
| Total Other Income/Expenses | -7.83M | -5.33M | -6.68M | 1.97M | -5.50M | -4.55M | -20.02M | 850.05K | 1.25M | 1.03M | 2.81M | 595.91K | -113.38K | 2.18M | 163.33K | 384.12K | 0.00 | -402.84K |
| Income Before Tax | -39.26M | -24.53M | -22.47M | -27.16M | -45.60M | -26.99M | -40.78M | -10.01M | -16.56M | -6.56M | -2.75M | -3.11M | -4.60M | 3.98M | -11.57M | -15.46M | 0.00 | -2.65M |
| Income Before Tax Ratio | -51.08% | -38.94% | -53.44% | -53.55% | -74.93% | -41.97% | -62.87% | -625.74% | -325.86% | -82.19% | -41.15% | -33.18% | -58.73% | 33.44% | -404.45% | -4,152.52% | 0.00% | -356.21% |
| Income Tax Expense | 584.00K | 156.00K | 142.00K | 275.00K | 191.00K | 304.00K | 387.00K | 850.05K | 1.25M | 1.03M | 2.81M | 595.91K | -113.38K | 2.18M | 175.45K | 42.00K | 0.00 | -86.79K |
| Net Income | -39.84M | -24.68M | -22.61M | -27.43M | -45.79M | -27.29M | -41.17M | -10.01M | -16.56M | -6.56M | -2.75M | -3.11M | -4.60M | 3.98M | -11.46M | -15.09M | -5.60M | -2.80M |
| Net Income Ratio | -51.84% | -39.18% | -53.77% | -54.09% | -75.24% | -42.44% | -63.46% | -625.74% | -325.86% | -82.19% | -41.15% | -33.18% | -58.73% | 33.44% | -400.54% | -4,053.13% | -1,094.97% | -376.28% |
| EPS | -0.98 | -0.82 | -0.99 | -1.27 | -2.31 | -2.01 | -105.69 | -29.95 | -77.00 | -37.61 | -19.74 | -26.65 | -44.48 | 39.63 | -128.50 | -209.81 | -123.52 | -365.69 |
| EPS Diluted | -0.98 | -0.82 | -0.99 | -1.27 | -2.31 | -2.01 | -105.69 | -29.95 | -77.00 | -37.61 | -19.74 | -26.65 | -44.48 | 37.78 | -128.50 | -209.81 | -123.52 | -365.69 |
| Weighted Avg Shares Out | 40.65M | 30.24M | 22.76M | 21.54M | 19.79M | 13.57M | 389.50K | 334.22K | 215.01K | 174.53K | 139.44K | 116.83K | 103.46K | 100.52K | 89.18K | 71.93K | 45.38K | 7.65K |
| Weighted Avg Shares Out (Dil) | 40.65M | 30.24M | 22.76M | 21.54M | 19.79M | 13.57M | 389.50K | 334.22K | 215.01K | 174.53K | 139.44K | 116.83K | 103.46K | 105.43K | 89.18K | 71.93K | 45.38K | 7.65K |
Weight Loss Services Market Analysis Report 2024-2030, Featuring Profiles of Atkins Nutritionals, Precor, Apollo Endosurgery, Johnson Health Tech, Life Fitness, iFIT, Torque Fitness and More
Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Weight Loss Services Market Size, Share and Trends Analysis Report by Function (Fitness Equipment, Surgical Equipment, Services), Payment (Out-of-Pocket, Government, Private), and Region 2024-2030" report has been added to ResearchAndMarkets.com's offering. The...
APOLLO ENDOSURGERY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apollo Endosurgery, Inc. - APEN
NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apollo Endosurgery, Inc. (NasdaqGM: APEN) to Boston Scientific Corporation...
SHAREHOLDER ALERT: Weiss Law Investigates Apollo Endosurgery, Inc.
NEW YORK , Nov. 29, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Apollo Endosurgery, Inc. ("Apollo Endosurgery" or the "Company") (NASDAQ: APEN), in connection with...
Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham
Boston Scientific Corp.'s BSX, +0.88% $615 million acquisition of Apollo Endosurgery Inc. APEN, +65.50% announced earlier is complementary to the former's endoscopy franchise, as it leverages its gastroenterologist call point while offering the potential for it to expand into surgical...
Apollo Endosurgery Stock Soars on Buyout Buzz
Apollo Endosurgery Inc (NASDAQ:APEN) stock is soaring, up 63.4% at $9.80 at last glance, after news that Boston Scientific Corp (BSX) will acquire the medical equipment name for $417 million.
Boston Scientific to acquire Apollo Endosurgery for $615 million in cash
Boston Scientific Corp. BSX, -0.82% said Tuesday it has agreed to acquire Apollo Endosurgery Inc. APEN, for $10 a share, or about $615 million in cash. The news sent Apollo's stock, which closed Monday at $6, up 61% in premarket...
Apollo Endosurgery to be Acquired by Boston Scientific
Boston Scientific to acquire Apollo for $10.00 per share in cash AUSTIN, TX / ACCESSWIRE / November 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it...
Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.
Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass. , Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc....
Apollo Endosurgery, Inc. (APEN) Q3 2022 Earnings Call Transcript
Apollo Endosurgery, Inc. (NASDAQ:APEN ) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Matt Kreps – Investor Relations Chas McKhann – Chief Executive Officer Jeff Black – Chief Financial Officer Conference Call Participants Mathew Blackman...
Apollo Endosurgery to Report Third Quarter Results on November 1, 2022
AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial...
Source: https://incomestatements.info
Category: Stock Reports